fenfluramine has been researched along with Insulin Resistance in 25 studies
Fenfluramine: A centrally active drug that apparently both blocks serotonin uptake and provokes transport-mediated serotonin release.
fenfluramine : A secondary amino compound that is 1-phenyl-propan-2-amine in which one of the meta-hydrogens is substituted by trifluoromethyl, and one of the hydrogens attached to the nitrogen is substituted by an ethyl group. It binds to the serotonin reuptake pump, causing inhbition of serotonin uptake and release of serotonin. The resulting increased levels of serotonin lead to greater serotonin receptor activation which in turn lead to enhancement of serotoninergic transmission in the centres of feeding behavior located in the hypothalamus. This suppresses the appetite for carbohydrates. Fenfluramine was used as the hydrochloride for treatment of diabetes and obesity. It was withdrawn worldwide after reports of heart valve disease and pulmonary hypertension.
Insulin Resistance: Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effect of the serotonergic agent dexfenfluramine on weight loss, blood pressure, insulin sensitivity and serum lipid levels was determined in a 3-month randomised, double-blind, placebo controlled parallel design study in 50 obese subjects (body mass index 30-44 kg/m2)." | 9.08 | Effect of dexfenfluramine on body weight, blood pressure, insulin resistance and serum cholesterol in obese individuals. ( Gamble, G; Holdaway, IM; Wallace, E; Westbrooke, L, 1995) |
| "3 ng/mL, means +/- SE), the clinical and metabolic effects of benfluorex (B), a lipid-lowering drug able to improve insulin sensitivity." | 9.08 | Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo. ( Camisasca, R; Cassisa, C; Pacchioni, M; Piatti, PM; Pontiroli, AE; Pozza, G, 1996) |
| "To evaluate the change in lipids and insulin sensitivity in 10 obese type II diabetic patients after treatment with benfluorex or placebo for 2 wk." | 9.07 | Effects of benfluorex on insulin resistance and lipid metabolism in obese type II diabetic patients. ( Bianchi, R; Bongers, V; Bravenboer, B; Erkelens, DW, 1993) |
| "We have examined the effect of chronic (20 days) oral administration of benfluorex (35 mg/kg) in a rat model of NIDDM, induced by injection of STZ 5 days after birth and characterized by frank hyperglycemia, hypoinsulinemia, and hepatic and peripheral insulin resistance." | 7.68 | Benfluorex normalizes hyperglycemia and reverses hepatic insulin resistance in STZ-induced diabetic rats. ( Bailbe, D; Blondel, O; Portha, B; Serradas, P, 1993) |
| "D-fenfluramine treatment markedly improved the maximum relaxant response of aortic rings to acetylcholine, indicating improvement of the defective endothelium-derived relaxation factor system." | 5.30 | Improvement of insulin sensitivity and cardiovascular outcomes in the JCR:LA-cp rat by D-fenfluramine. ( Amy, RM; Brindley, DN; Dolphin, PJ; Graham, SE; Russell, JC, 1998) |
| "The effect of the serotonergic agent dexfenfluramine on weight loss, blood pressure, insulin sensitivity and serum lipid levels was determined in a 3-month randomised, double-blind, placebo controlled parallel design study in 50 obese subjects (body mass index 30-44 kg/m2)." | 5.08 | Effect of dexfenfluramine on body weight, blood pressure, insulin resistance and serum cholesterol in obese individuals. ( Gamble, G; Holdaway, IM; Wallace, E; Westbrooke, L, 1995) |
| "3 ng/mL, means +/- SE), the clinical and metabolic effects of benfluorex (B), a lipid-lowering drug able to improve insulin sensitivity." | 5.08 | Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo. ( Camisasca, R; Cassisa, C; Pacchioni, M; Piatti, PM; Pontiroli, AE; Pozza, G, 1996) |
| "To evaluate the change in lipids and insulin sensitivity in 10 obese type II diabetic patients after treatment with benfluorex or placebo for 2 wk." | 5.07 | Effects of benfluorex on insulin resistance and lipid metabolism in obese type II diabetic patients. ( Bianchi, R; Bongers, V; Bravenboer, B; Erkelens, DW, 1993) |
| " Chronic treatment of rats with D-fenfluramine has been shown to decrease the release of cortisol and fatty acids in response to stress, and to improve insulin sensitivity." | 4.79 | Role of glucocorticoids and fatty acids in the impairment of lipid metabolism observed in the metabolic syndrome. ( Brindley, DN, 1995) |
| " Benfluorex treatment improves insulin sensitivity and has antihyperglycemic and hypolipidemic effects in human beings and in experimental animals." | 4.78 | [Mode of action of benfluorex. Recent data]. ( Brindley, DN, 1992) |
| "It has been reported that benfluorex ameliorates the insulin resistance induced by high-fat feeding when its administration is initiated at the same time as the change in diet." | 3.70 | Benfluorex improves muscle insulin responsiveness in middle-aged rats previously subjected to long-term high-fat feeding. ( Gumà, A; Muñoz, P; Palacín, M; Sevilla, L; Testar, X; Zorzano, A, 1999) |
| "We have examined the effect of chronic (21 days) oral administration of the serotoninergic anorectic drug d-fenfluramine (5 mg/kg) in a rat model of non-insulin-dependent diabetes (without obesity), as induced by injection of a low dose (45 mg/kg) of streptozotocin at 6 weeks, and characterized by marked hyperglycaemia and hepatic and peripheral insulin resistance." | 3.69 | d-Fenfluramine improves hepatic insulin action in streptozotocin-diabetic rats. ( Bailbé, D; Picarel-Blanchot, F; Portha, B, 1994) |
| " Benfluorex has both anorectic and metabolic effects that lower body weight and improve insulin sensitivity in obesity and type 2 diabetes." | 3.69 | Antiatherogenic effects of long-term benfluorex treatment in male insulin resistant JCR:LA-cp rats. ( Amy, RM; Brindley, DN; Dolphin, PJ; Graham, SE; Russell, JC; Wood, GO, 1997) |
| "We have examined the effect of chronic (20 days) oral administration of benfluorex (35 mg/kg) in a rat model of NIDDM, induced by injection of STZ 5 days after birth and characterized by frank hyperglycemia, hypoinsulinemia, and hepatic and peripheral insulin resistance." | 3.68 | Benfluorex normalizes hyperglycemia and reverses hepatic insulin resistance in STZ-induced diabetic rats. ( Bailbe, D; Blondel, O; Portha, B; Serradas, P, 1993) |
| "Benfluorex + insulin is a valid alternative for obese patients who remain poorly controlled despite insulin or who require high doses of insulin." | 2.69 | Added benfluorex in obese insulin-requiring type 2 diabetes. ( Bauduceau, B; Brun, JM; Guillon-Metz, F; Leutenegger, M; Martin, C; Nicolino-Peltier, C; Richard, JL; Vannereau, D, 1998) |
| "Insulin resistance is one of the cardinal pathophysiological components of the metabolic syndrome, type 2 diabetes, and frequently co-exists with essential hypertension." | 2.40 | Insulin resistance: site of the primary defect or how the current and the emerging therapies work. ( Caro, JF; Kolaczynski, JW, 1998) |
| "The relief of insulin resistance is one of the two therapeutic targets of the treatment of type 2 diabetes." | 2.40 | [Current status of the treatment of type 2 diabetes mellitus. The revival of insulin-resistance drugs]. ( Andres, E; Blicklé, JF; Brogard, JM; Neyrolles, N, 1999) |
| "D-fenfluramine treatment markedly improved the maximum relaxant response of aortic rings to acetylcholine, indicating improvement of the defective endothelium-derived relaxation factor system." | 1.30 | Improvement of insulin sensitivity and cardiovascular outcomes in the JCR:LA-cp rat by D-fenfluramine. ( Amy, RM; Brindley, DN; Dolphin, PJ; Graham, SE; Russell, JC, 1998) |
| "Benfluorex-treated animals showed significant decreases in glucose intolerance, hyperinsulinemia, hypertriglyceridemia, hypercholesterolemia, and plasma LDL- and VLDL-cholesterol, with no evidence of aortic atheroma." | 1.30 | Metabolic and anti-atherogenic effects of long-term benfluorex in dyslipidemic insulin-resistant sand rats (Psammomys obesus). ( Bennani, N; El Madani, T; Hadjiisky, P; Marquié, G; Pieraggi, MT; Ravel, D; Seguin, L; Solera, ML, 1998) |
| "Dexfenfluramine has been shown to lower blood glucose concentrations independently of its effects in reducing food intake and body weight, in human and animal syndromes of non-insulin dependent diabetes." | 1.29 | Acute dexfenfluramine administration normalizes glucose tolerance in rats with insulin-deficient diabetes. ( Arora, R; Dryden, S; McKibbin, PE; Williams, G, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.00) | 18.7374 |
| 1990's | 23 (92.00) | 18.2507 |
| 2000's | 1 (4.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Muldoon, MF | 1 |
| Mackey, RH | 1 |
| Williams, KV | 1 |
| Korytkowski, MT | 1 |
| Flory, JD | 1 |
| Manuck, SB | 1 |
| Després, JP | 1 |
| Lemieux, S | 1 |
| Lamarche, B | 1 |
| Prud'homme, D | 1 |
| Moorjani, S | 1 |
| Brun, LD | 1 |
| Gagné, C | 1 |
| Lupien, PJ | 1 |
| Brindley, DN | 5 |
| Picarel-Blanchot, F | 1 |
| Bailbé, D | 2 |
| Portha, B | 2 |
| Arora, R | 1 |
| Dryden, S | 1 |
| McKibbin, PE | 1 |
| Williams, G | 1 |
| Storlien, LH | 3 |
| Pan, DA | 2 |
| Kusunoki, M | 2 |
| Cooney, GJ | 1 |
| Lacour, F | 1 |
| Espinal, J | 1 |
| Arnaud, O | 1 |
| Duhault, J | 1 |
| Oakes, ND | 1 |
| Jenkins, AB | 2 |
| Serradas, P | 1 |
| Blondel, O | 1 |
| Bianchi, R | 1 |
| Bongers, V | 1 |
| Bravenboer, B | 1 |
| Erkelens, DW | 1 |
| Holdaway, IM | 1 |
| Wallace, E | 1 |
| Westbrooke, L | 1 |
| Gamble, G | 1 |
| Pontiroli, AE | 1 |
| Pacchioni, M | 1 |
| Piatti, PM | 1 |
| Cassisa, C | 1 |
| Camisasca, R | 1 |
| Pozza, G | 1 |
| Russell, JC | 2 |
| Graham, SE | 2 |
| Dolphin, PJ | 2 |
| Amy, RM | 2 |
| Wood, GO | 1 |
| Leutenegger, M | 1 |
| Bauduceau, B | 1 |
| Brun, JM | 1 |
| Guillon-Metz, F | 1 |
| Martin, C | 1 |
| Nicolino-Peltier, C | 1 |
| Richard, JL | 1 |
| Vannereau, D | 1 |
| Marquié, G | 1 |
| El Madani, T | 1 |
| Solera, ML | 1 |
| Pieraggi, MT | 1 |
| Hadjiisky, P | 1 |
| Ravel, D | 1 |
| Seguin, L | 1 |
| Bennani, N | 1 |
| Sevilla, L | 1 |
| Gumà, A | 1 |
| Muñoz, P | 1 |
| Testar, X | 1 |
| Palacín, M | 1 |
| Zorzano, A | 1 |
| Kolaczynski, JW | 1 |
| Caro, JF | 1 |
| Brogard, JM | 1 |
| Neyrolles, N | 1 |
| Andres, E | 1 |
| Blicklé, JF | 1 |
| Horácek, J | 1 |
| Kuzmiaková, M | 1 |
| Höschl, C | 1 |
| Andĕl, M | 1 |
| Bahbonh, R | 1 |
| Sodoyez, JC | 1 |
| Sodoyez-Goffaux, F | 1 |
| Thorburn, AW | 1 |
| Smythe, GA | 1 |
| Chisholm, DJ | 1 |
| Kraegen, EW | 1 |
7 reviews available for fenfluramine and Insulin Resistance
| Article | Year |
|---|---|
The insulin resistance-dyslipidemic syndrome: contribution of visceral obesity and therapeutic implications.
Topics: Adipose Tissue; Cardiovascular Diseases; Fenfluramine; Humans; Hyperlipidemias; Insulin Resistance; | 1995 |
Role of glucocorticoids and fatty acids in the impairment of lipid metabolism observed in the metabolic syndrome.
Topics: Animals; Fatty Acids; Fatty Acids, Nonesterified; Fenfluramine; Glucocorticoids; Humans; Hydrocortis | 1995 |
Mechanisms for the effects of benfluorex on the obese-diabetic-dyslipidemic syndrome.
Topics: Animals; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fenfluramine; Humans; Hyperlipidemias; Hypogl | 1993 |
Effects of benfluorex on in vivo patterns of insulin resistance induced by diets rich in fat or fructose.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diet, Diabetic; Dietary Carbohydrates; Dietary Fa | 1993 |
Insulin resistance: site of the primary defect or how the current and the emerging therapies work.
Topics: Adipose Tissue; Appetite Depressants; Diabetes Mellitus, Type 2; Female; Fenfluramine; Humans; Hypog | 1998 |
[Current status of the treatment of type 2 diabetes mellitus. The revival of insulin-resistance drugs].
Topics: Administration, Oral; Chromans; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Exercise; Fenfluramine | 1999 |
[Mode of action of benfluorex. Recent data].
Topics: Animals; Arteriosclerosis; Diabetes Mellitus, Type 2; Drug Interactions; Fatty Acids; Female; Fenflu | 1992 |
4 trials available for fenfluramine and Insulin Resistance
| Article | Year |
|---|---|
Effects of benfluorex on insulin resistance and lipid metabolism in obese type II diabetic patients.
Topics: Apolipoprotein A-I; Apolipoproteins B; Appetite Depressants; Blood Glucose; C-Peptide; Cholesterol; | 1993 |
Effect of dexfenfluramine on body weight, blood pressure, insulin resistance and serum cholesterol in obese individuals.
Topics: Adult; Blood Pressure; Body Mass Index; Body Weight; Cholesterol; Dose-Response Relationship, Drug; | 1995 |
Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo.
Topics: 3-Hydroxybutyric Acid; Appetite Depressants; Body Weight; C-Peptide; Diabetes Mellitus; Diabetes Mel | 1996 |
Added benfluorex in obese insulin-requiring type 2 diabetes.
Topics: Adolescent; Adult; Aged; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus; Diabetes Mellitus | 1998 |
14 other studies available for fenfluramine and Insulin Resistance
| Article | Year |
|---|---|
Low central nervous system serotonergic responsivity is associated with the metabolic syndrome and physical inactivity.
Topics: Adult; Blood Glucose; Blood Pressure; Body Mass Index; Brain; Female; Fenfluramine; Humans; Insulin; | 2004 |
d-Fenfluramine improves hepatic insulin action in streptozotocin-diabetic rats.
Topics: Administration, Oral; Analysis of Variance; Animals; Blood Glucose; Diabetes Mellitus, Experimental; | 1994 |
Acute dexfenfluramine administration normalizes glucose tolerance in rats with insulin-deficient diabetes.
Topics: Animals; Blood Glucose; Corticosterone; Diabetes Mellitus, Experimental; Dose-Response Relationship, | 1994 |
Insulin resistance, hyperinsulinemia and diabetes--contribution of benfluorex. Prague, 11 September 1992. Symposium proceedings.
Topics: Animals; Diabetes Mellitus, Type 2; Fenfluramine; Humans; Hyperinsulinism; Hypoglycemic Agents; Insu | 1993 |
Improvement in glucose tolerance of insulin resistant rats after chronic or acute administration of benfluorex.
Topics: Administration, Oral; Animals; Blood Glucose; Drug Administration Schedule; Fenfluramine; Glucose In | 1993 |
Syndromes of insulin resistance in the rat. Inducement by diet and amelioration with benfluorex.
Topics: Analysis of Variance; Animals; Diet; Dietary Carbohydrates; Dietary Fats; Disease Models, Animal; Fe | 1993 |
Benfluorex normalizes hyperglycemia and reverses hepatic insulin resistance in STZ-induced diabetic rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Female; Fenflura | 1993 |
Antiatherogenic effects of long-term benfluorex treatment in male insulin resistant JCR:LA-cp rats.
Topics: Animals; Arteriosclerosis; Fenfluramine; Hypolipidemic Agents; Insulin Resistance; Male; Obesity; Ra | 1997 |
Improvement of insulin sensitivity and cardiovascular outcomes in the JCR:LA-cp rat by D-fenfluramine.
Topics: Acetylcholine; Animals; Aorta; Aorta, Thoracic; Aortic Diseases; Appetite Depressants; Arteriosclero | 1998 |
Metabolic and anti-atherogenic effects of long-term benfluorex in dyslipidemic insulin-resistant sand rats (Psammomys obesus).
Topics: Animal Nutritional Physiological Phenomena; Animals; Aorta; Arteriosclerosis; Body Weight; Cholester | 1998 |
Benfluorex improves muscle insulin responsiveness in middle-aged rats previously subjected to long-term high-fat feeding.
Topics: Aging; Animals; Biological Transport; Blood Glucose; Blotting, Northern; Body Weight; Deoxyglucose; | 1999 |
The relationship between central serotonergic activity and insulin sensitivity in healthy volunteers.
Topics: Adult; Blood Glucose; Body Constitution; Body Mass Index; Brain; Fenfluramine; Glucose Clamp Techniq | 1999 |
[Effects of chronic administration of benfluorex on the pharmacokinetics of iodine 123 labelled insulin in Zucker obese rats (fa/fa)].
Topics: Administration, Oral; Animals; Fenfluramine; Hypolipidemic Agents; Insulin; Insulin Resistance; Iodi | 1992 |
Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.
Topics: Adipose Tissue; Adipose Tissue, Brown; Animals; Blood Glucose; Dietary Carbohydrates; Dietary Fats; | 1989 |